Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy

Current Atherosclerosis Reports
Neha QuatromoniJay Giri

Abstract

Dual anti-platelet therapy, most commonly aspirin and clopidogrel, has been the standard of care for over a decade in patients who have experienced acute coronary syndrome, particularly when treated with coronary stenting. However, residual risk in patients receiving dual anti-platelet therapy post-acute coronary syndrome raises an unmet need for alternative therapy to clopidogrel. Consequently, novel anti-platelets agents including the P2Y12 receptor antagonists, such as prasugrel and ticagrelor, have emerged. Furthermore, using new methods to assess genetic polymorphisms and functional phenotypic assessments of platelet reactivity may become important in the development of personalized medicine and in developing tailored approaches to individual treatment. While robust large-scale evidence for genotypic- and phenotypic-guided therapy in improving outcomes is currently lacking, tremendous interest from various stakeholders including researchers, funding agencies, and industry continues to spur research endeavors in this arena. Further investigation is required in this emerging field to potentially offer improved platelet inhibition that may optimize cardioprotection and minimize bleeding risk in patients with acute coronary sy...Continue Reading

References

Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Sep 25, 2002·Journal of Internal Medicine·P JäremoA Richter
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Oct 30, 2008·Nature Clinical Practice. Cardiovascular Medicine·Nina C RajuJack Hirsh
Dec 25, 2008·The New England Journal of Medicine·Jessica L MegaMarc S Sabatine
May 20, 2009·Circulation·Matthew J Price
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Nov 17, 2009·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PLATFORM Investigators
Oct 29, 2010·The New England Journal of Medicine·Guillaume ParéJohn W Eikelboom
Mar 17, 2011·JAMA : the Journal of the American Medical Association·Matthew J PriceUNKNOWN GRAVITAS Investigators
Apr 27, 2011·American Journal of Therapeutics·Suraj ChandrasekarRohit Arora
Dec 29, 2011·JAMA : the Journal of the American Medical Association·Michael V HolmesJuan P Casas
Mar 7, 2012·Pharmacotherapy·Kathleen A PackardEstella M Davis
Aug 28, 2012·The New England Journal of Medicine·Matthew T RoeUNKNOWN TRILOGY ACS Investigators
Nov 3, 2012·JAMA : the Journal of the American Medical Association·Paul A GurbelUNKNOWN TRILOGY ACS Platelet Function Substudy Investigators
Nov 6, 2012·The New England Journal of Medicine·Jean-Philippe ColletUNKNOWN ARCTIC Investigators
Dec 20, 2012·Current Cardiology Reports·Andrew R Harper, Matthew J Price
May 24, 2013·Clinical Pharmacology and Therapeutics·S A ScottUNKNOWN Clinical Pharmacogenetics Implementation Consortium

❮ Previous
Next ❯

Citations

Mar 1, 2018·Current Treatment Options in Cardiovascular Medicine·Daniel R MangelsTaisei Kobayashi
Jul 27, 2021·Ophthalmic Surgery, Lasers & Imaging Retina·Matthew R StarrAllen Chiang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Pharmacotherapy
Wah Wah Htun, Steven R Steinhubl
Journal of Cardiovascular Translational Research
Paul W A Janssen, Jurrien M ten Berg
Current Treatment Options in Cardiovascular Medicine
Rahil RafeedheenPaul A Gurbel
© 2022 Meta ULC. All rights reserved